1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
China National Medicines Corporation Ltd.

China National Medicines Corporation Ltd.

600511.SS
China National Medicines Corporation Ltd.CN flagShanghai Stock Exchange
27.02
CNY
-0.38
- -
20.39BMarket Cap
China National Medicines Corporation Ltd.
600511.SS
(Shanghai Stock Exchange)

Recent

price

27.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
12.36
14.71
17.94
21.06
24.1
25.23
49.92
49.28
50.53
58.59
53.52
61.59
60.3
65.87
67.06
69.54
52.44
Revenue per Share
0.65
0.57
0.7
0.86
1.01
1.07
1.43
1.55
1.83
2.11
1.83
2.32
2.6
2.84
2.65
2.65
1.95
Basic EPS, GAAP
0.61
-0.9
0.03
0.13
0.15
0.78
1.43
1.36
1.11
2.22
1.63
2.47
3
3.42
2.03
2.57
-0.06
Free Cash Flow per Basic Share
0.16
0.22
0.15
0.3
0.36
0.18
0.28
0.35
0.67
0.59
0.81
0.85
0.81
0.94
0.9
0.83
0.82
Dividend per Share
2.33
2.7
3.28
3.84
4.5
5.38
5.95
7.33
8.3
9.92
11.21
12.99
14.89
16.95
18.75
20.59
21.22
Book Value per Share
2.78
3.18
3.75
4.43
5.2
7.14
9.86
12.26
13.26
15.26
16.65
18.32
20.31
22.46
24.36
26.18
26.88
Tangible Book Value per Share
479
479
479
479
479
479
693
736
767
762
754
755
755
754
755
755
754
Basic Weighted Avg Shares
5,918
7,042
8,592
10,081
11,538
12,078
34,611
36,285
38,740
44,644
40,379
46,469
45,499
49,696
50,597
52,468
39,563
Sales/Revenue/Turnover
5.22
2.94
2.91
3.9
4.45
4.52
4.46
4.76
4.93
5.27
4.22
4.73
5.28
4.94
4.22
3.95
3.84
Operating Margin (%)
17
20
23
24
32
42
76
80
87
130
173
179
190
200
241
238
- -
Depreciation Expense
310
271
336
412
483
513
990
1,141
1,404
1,604
1,383
1,754
1,964
2,146
2,000
1,997
1,468
Net Income, GAAP
21.45
19.2
18.86
19.65
20.3
20.28
23.08
23.07
21.28
22.5
21.28
21.12
20.8
20.35
19.74
19.64
19.14
Effective Tax Rate (%)
5.24
3.85
3.91
4.08
4.18
4.25
2.86
3.15
3.62
3.59
3.42
3.77
4.32
4.32
3.95
3.81
3.71
Profit Margin (%)
1,257
1,274
1,234
1,403
1,704
2,420
5,761
7,852
8,696
10,073
10,872
11,845
13,025
14,385
15,501
16,589
16,957
Working Capital
- -
- -
- -
- -
100
- -
- -
- -
125
167
260
197
183
205
261
192
215
LT Debt
1,343
1,533
1,869
2,196
2,581
3,514
7,269
9,456
10,610
12,159
13,094
14,355
15,859
17,533
18,975
20,308
20,827
Total Equity
20.53
11.77
11.58
13.88
14.91
13.08
20.94
14.49
13.4
14.87
10.04
11.91
12.03
11.31
9.03
8.2
5.86
Return on Invested Capital (%)
31.65
23.97
23.22
20.61
20.34
17.42
16.76
15.39
16.15
14.69
12.6
14.04
14.29
13.92
11.88
11.11
7.97
Return on Capital (%)
31.04
22.54
23.48
24.14
24.16
21.68
29.55
23.96
23.88
23.05
17.26
19.21
18.68
17.87
14.85
13.45
9.59
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
324
292
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
192
215
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
755
755
Market Capitalization
21,578
21,691
22,106

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
31,991
31,311
Cash, Cash Equivalents & STI
- -
11,482
7,811
Accounts Receivable, Net
- -
12,750
15,644
Inventories
- -
5,192
5,183
Total Current Liabilities
- -
15,402
14,355
Payables & Accruals
- -
- -
- -
ST Debt
- -
324
292
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.73%
9.18%
7.03%
Free Cash Flow
29.73%
14.53%
26.76%
Net Income, GAAP
17.29%
8.22%
-0.18%
Sales/Revenue/Turnover
23.16%
5.55%
3.7%
Total Cash Common Dividend
29.06%
0.76%
-8.31%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,122
12,634
13,272
12,569
50,597
2025
12,713
12,921
- -
13,087
52,468
2026
13,555
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.61
- -
- -
- -
2.65
2025
0.61
- -
- -
- -
2.65
2026
0.63
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
- -
- -
- -
0.9
2025
0.01
- -
- -
- -
0.83
2026
0.01
- -
- -
- -
- -
Similar Companies
Zydus Lifesciences Limited (CADILAHC.NS)
PT Phapros, Tbk (PEHA.JK)
Revive Therapeutics Ltd. (RVV.CN)
SLANG Worldwide Inc. (SLNG.CN)
Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS)
Ilyang Pharmaceutical Co.,Ltd (007575.KS)
Business
China National Medicines Corporation Ltd. (600511.SS) engages principally in the distribution, manufacturing, and sale of pharmaceutical products in China. The company offers pharmaceutical direct sales including new drugs, finished drugs, Chinese patent medicines, western medicines, and medical equipment; warehousing services; logistics; and import/export agency services, with a specialization in anesthetics, psychiatric drugs, high-end prescription drugs, essential medicines, and blood products. It primarily serves hospitals, retail pharmacies, and medical institutions, with operations focused on the Beijing market and nationwide distribution. Founded in 1999 and headquartered in Beijing, the company operates as a subsidiary of Sinopharm Group Co. Ltd. Recent activities include Sinopharm's signing of 20 procurement agreements at the seventh China International Import Expo in November 2024 for high-end medical equipment, medical devices, and imported health products, enhancing supply chain capabilities.